9,10-dimethyl-1,2-benzanthracene has been researched along with sirolimus in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amornphimoltham, P; Gutkind, JS; Leelahavanichkul, K; Molinolo, A; Patel, V | 1 |
| Kennedy, GD; Lambert, PF; Lee, D; Liem, A; Pitot, HC; Stelzer, MK | 1 |
| Checkley, LA; DiGiovanni, J; Hursting, S; Moore, T; Rho, O | 1 |
| Callaway, D; Curiel, TJ; Dao, V; Dodds, S; Hasty, P; Hurez, V; Liu, A; Liu, Y; Pandeswara, S; Sharp, ZD | 1 |
| Amornphimoltham, P; Califano, JA; Callejas-Valera, JL; Gutkind, JS; Iglesias-Bartolome, R; Martin, D; Molinolo, AA; Palacios-Garcia, J | 1 |
| Curiel, TJ; Dao, V; Gelfond, JA; Hurez, V; Liu, A; Liu, Y; Pandeswara, S; Svatek, RS | 1 |
6 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and sirolimus
| Article | Year |
|---|---|
Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carrier Proteins; Female; Mice; Phosphotransferases (Alcohol Group Acceptor); Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases | 2008 |
Rapamycin inhibits anal carcinogenesis in two preclinical animal models.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antibiotics, Antineoplastic; Anus Neoplasms; Blotting, Western; Carcinogens; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Mice, SCID; Mice, Transgenic; Oncogene Proteins, Viral; Papilloma; Papillomaviridae; Papillomavirus E7 Proteins; Repressor Proteins; Sirolimus | 2010 |
Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Blotting, Western; Carcinogens; Humans; Hyperplasia; Mice; Neoplasm Staging; Papilloma; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Skin Neoplasms; Tetradecanoylphorbol Acetate; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2011 |
Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage.
Topics: 3T3 Cells; 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogenesis; Carcinogens; Cells, Cultured; Chemoprevention; DNA Damage; Down-Regulation; Humans; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Sirolimus; Skin Neoplasms | 2015 |
mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinogens; Carcinoma, Squamous Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Human papillomavirus 16; Humans; Mice; Oncogene Proteins, Viral; Oropharyngeal Neoplasms; Papillomavirus E7 Proteins; Papillomavirus Infections; Phorbol Esters; Repressor Proteins; Sirolimus; TOR Serine-Threonine Kinases | 2016 |
Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adjuvants, Immunologic; Animals; Cell Movement; Chemokine CXCL10; Cytotoxicity, Immunologic; Female; Humans; Interferon-gamma; Mice; Mice, Inbred C57BL; Receptors, Antigen, T-Cell, gamma-delta; Receptors, CXCR3; Sirolimus; Skin Neoplasms; T-Lymphocyte Subsets; TOR Serine-Threonine Kinases | 2016 |